Trulieve Cannabis Corp.
TRLVNYSE
$8.79
↑ +4.5%Jul 17 close · end-of-day
Price
1Y↑ +114.9%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$1.7B
Enterprise Value
$1.6B
P/E
—
P/S
1.5
P/B
1.5
EV/EBITDA
6.0
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$1.2B
Net Income (TTM)
—
Free Cash Flow (TTM)
—
Gross Margin
59.7%
Operating Margin
12.5%
Net Margin
—
ROE
—
ROIC
7.3%
Debt / Equity
0.2
Net Cash
$157.2M
Return 1Y
+113.3%
Company profile
Trulieve Cannabis Corp., together with its subsidiaries, operates as a medical cannabis company. The company cultivates and produces products in-house and distributes its products to Trulieve branded stores (dispensaries) in Florida, California, Massachusetts, Connecticut, Pennsylvania, and West Virginia, as well as directly to patients through home delivery. It produces approximately 550 stock keeping units, including flower, edibles, vaporizer cartridges, concentrates, topicals, capsules, tinctures, dissolvable powders, and nasal sprays. As of May 5, 2021, the company operated through 87 dispensaries in the United States. The company is headquartered in Quincy, Florida.
- CEO
- N/A
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 9,000
- Headquarters
- Florida
- Website
- trulieve.com
Earnings
TRLV Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$286.8M↓ -3.7%
Diluted EPS——
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $521.5M | $931.9M | $1.2B | $1.1B | $1.2B | $1.2B |
| Gross profit | $386.4M | $566.6M | $689.1M | $588.6M | $715.7M | $711.2M |
| Operating income | $218.3M | $204.1M | $50.2M | -$221.6M | $97.8M | $143.5M |
| Net income | $63.0M | $18.0M | -$246.1M | -$526.8M | -$155.1M | -$116.4M |
| Diluted EPS | $0.53 | $0.21 | -$0.95 | -$2.28 | -$0.79 | -$0.58 |
| Operating cash flow | $99.6M | $12.9M | $23.1M | $201.8M | $271.5M | $272.8M |
| Free cash flow | -$298,000.00 | -$263.0M | -$141.7M | $161.6M | $148.9M | $228.6M |
| Gross margin | 74.1% | 60.8% | 56.6% | 52.1% | 60.3% | 60.2% |
| Operating margin | 41.9% | 21.9% | 4.1% | -19.6% | 8.2% | 12.1% |
| Net margin | 12.1% | 1.9% | -20.2% | -46.7% | -13.1% | -9.9% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $303.4M | $284.3M | $301.1M | $297.8M | $302.1M | $288.2M | $293.1M | $286.8M |
| Gross profit | $181.6M | $173.3M | $187.0M | $183.2M | $182.9M | $169.9M | $175.2M | $170.1M |
| Operating income | $49.8M | $618,000.00 | $1.3M | $33.3M | $52.6M | $42.2M | $15.3M | $35.7M |
| Net income | -$12.0M | -$61.6M | -$57.0M | — | — | — | — | — |
| Diluted EPS | -$0.04 | -$0.32 | -$0.27 | -$0.16 | — | — | — | — |
| Operating cash flow | $71.3M | $30.3M | $30.7M | $51.1M | $85.7M | $76.8M | $59.2M | $55.7M |
| Free cash flow | $45.0M | -$7.8M | -$12.0M | $34.2M | $74.1M | $64.4M | $55.8M | — |
| Gross margin | 59.9% | 61.0% | 62.1% | 61.5% | 60.6% | 58.9% | 59.8% | 59.3% |
| Operating margin | 16.4% | 0.2% | 0.4% | 11.2% | 17.4% | 14.7% | 5.2% | 12.5% |
| Net margin | -3.9% | -21.7% | -18.9% | — | — | — | — | — |
Company news
Jul 16, 2026
Jul 10, 2026
Jul 1, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.